Compare Medpace Holdings Inc (MEDP) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Royal Bank of Canada — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.87B), while Royal Bank of Canada trades at $192.67 (market cap $265.72B). The key difference: Royal Bank of Canada is far larger — about 15.8× Medpace Holdings Inc's market cap, and Royal Bank of Canada pays a 2.65% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Royal Bank of Canada for 47 Days on average.
| MEDP | RY | |
|---|---|---|
Market Cap | $16.87B | $265.72B |
Volume | 207,570 | 756,291 |
Sector | Health | Financials |
52-Week High | $630.19 | $217.87 |
52-Week Low | $393.42 | $143.64 |
Typical Hold Time | 14 Days | 47 Days |
Enterprise Value | $16.48B | $732.82B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Royal Bank of Canada (RY) trades at $190.56, down 2.95% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 beating estimates of $2.89 (Zacks Investment Research, August 27, 2026). Revenue growth accelerated to $66.53B in 2025, with net income margin improving to 32.01%. The company maintains a solid dividend payout of $1.76 per share, with the next payment scheduled for November 24, 2026.
RY presents a mixed investment case with strong profitability and dividend stability offset by stretched valuations and bearish technical indicators. The 17.2 P/E ratio suggests fair valuation, while analyst consensus leans neutral with 43% buy ratings. Key risks include macroeconomic sensitivity and competitive pressures in financial services. The stock's current technical weakness near support at $189 may present entry opportunities for long-term investors seeking quality banking exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
